Want to see HUMA full AI Analyst Report?
EarningsQ2 2026 Earnings Report
HUMA Q2 2026 EPS Results
Actual EPS-$0.16
Consensus EPS-$0.11
Beat/MissMissed by -$0.05
One Year Ago EPS-$0.24
HUMA Q2 2026 Revenue Results
Actual Revenue$406.00K
Expected Revenue$1.04M
Beat/MissMissed by -$634.00K
YoY Revenue Growth+34.88%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeBefore Open
Conference CallWednesday, August 12, 2026
HUMA Upcoming Earnings
Humacyte's next earnings date is estimated for November 6, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
HUMA Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory momentum (statistically significant V012 results, planned sBLA filing, IND acceptance for CTEV, commercial team overhaul and early commercial traction) which are material positives. However, near-term financials showed modest absolute sales, rising COGS and inventory reserves, a substantial six‑month loss driven by non-cash liability remeasurements, and continued operating spend. The operational and clinical progress appears to materially outweigh the current financial headwinds, which management is positioning to address as commercialization scales.Company Guidance
Breakthrough V012 Phase III Interim Results in Female Dialysis Patients
In a pre-specified interim analysis of the first 80 patients, ATEV produced 91 more catheter-free days versus AV fistula (p = 0.0007), meeting the primary efficacy endpoint. Infection rates were 6 vs 23 infections per 100 patient-years (≈74% reduction). Management characterized the result as a major advance for hemodialysis access.
Planned sBLA Filing and Potential Timelines for Dialysis Indication
Company plans to submit a supplemental BLA in H2 2026 (target November). Management will request priority review (leveraging RMAT designation); best‑case PDUFA in May 2027 and potential commercial launch in late Q2 2027. Application to include data from three Phase III and multiple Phase II studies (total exposure >1,000 patient-years).
IND Accepted for CTEV (Coronary) and Manufacturing Scale-Up
FDA accepted IND for first-in-human Phase IIa CTEV CABG study. Commercial-scale CTEV manufacturing lot completed; trial expected to initiate in the current quarter (Phase IIa ~10 patients). Manufacturing uses same platform as ATEV but expected demand for CTEV study is minimal relative to capacity.
Commercial Team Rebuild and Early Adoption Momentum for Symvess
New commercial leadership (CCO appointed in April; Chief Surgical Officer appointed) and remodeled commercial strategy (introductory pricing, VAC engagement, national account strategy). Management reports at least ~20 major U.S. healthcare systems in process of adopting Symvess in H2 2026 and increasing utilization at early adopter sites.
Quarter-over-Quarter and Year-over-Year Commercial Sales Improvement
Commercial sales of Symvess: $0.4M in Q2 2026 vs $0.1M in Q2 2025 (+300%), and $0.9M for six months 2026 vs $0.2M for six months 2025 (+350%).
Improved Cash Flow and Cash Balance
Cash, cash equivalents and restricted cash of $80.1M as of June 30, 2026. Total net cash provided of $29.4M in first six months of 2026 vs net cash used of $6.9M in the prior-year period (positive swing of $36.3M), driven by higher proceeds from sales of equities and reduced cash used in operations.
R&D Cost Reduction in Q2
Quarterly R&D decreased to $18.1M in Q2 2026 from $22.0M in Q2 2025 (≈-17.7%), attributed to reduced non-commercial manufacturing runs and lower clinical trial expenses in the quarter.
HUMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed